Mazdutide Peptide For Sale

Buy Mazdutide peptide: 10mg or 15mg listed purchase quantities. Compare live prices across 4 listed vendors with real cost per mg, recorded COA availability and discount codes.

Buy Mazdutide peptide starting at $67.15/purchase from 4 listed vendors. Compare 10mg and 15mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).

About Mazdutide

In clinical trialsAlso known as: LY3305677 · IBI362

Mazdutide is an investigational once-weekly GLP-1/glucagon dual-agonist peptide, sourced in research for weight and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.

What to check before you buy Mazdutide:

  • A third-party COA showing ≥98–99% purity by HPLC plus mass-spec confirmation of mazdutide's identity — not just an in-house "tested" badge.
  • A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
  • Accurate vial fill: a 10mg label should assay close to 10mg. Under-filled vials are the common failure mode and skew every reconstitution calculation.

GLORY-1 (Ji et al., NEJM 2025) reported mean placebo-subtracted weight reduction of approximately 14.0% at 48 weeks on the 9mg arm in Chinese adults with obesity, the first published Phase 3 GLP-1/glucagon dual-agonist obesity readout.[2] DREAMS-2 reported A1C reductions of ~1.6–2.1% at 9mg weekly in Chinese adults with T2D.[3] A Phase 2 hepatic-fat substudy reported MRI-PDFF reductions consistent with the GLP-1/glucagon class signal.[4] Lilly retains worldwide rights outside greater China and has not announced a U.S. registration program.

Regulatory: Not FDA- or EMA-approved. Innovent has filed for Chinese NMPA approval for obesity and T2D based on GLORY-1 / DREAMS-1. Research-grade material elsewhere.

Read the full mechanism & research breakdown

Mazdutide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Mazdutide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Mazdutide is an oxyntomodulin-mimetic synthetic peptide that binds two gut-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. The molecule is engineered as a derivative of native oxyntomodulin — the endogenous proglucagon-derived peptide that naturally activates both receptors — with structural modifications and a fatty-acid sidechain that extend the half-life to support once-weekly subcutaneous dosing.[5] The GLP-1 arm slows gastric emptying, amplifies glucose-dependent insulin secretion, suppresses glucagon postprandially, and reduces appetite through hypothalamic signalling — the same mechanisms as semaglutide. The glucagon arm is the differentiator: chronic glucagon-receptor agonism increases resting energy expenditure and accelerates hepatic lipolysis, the leading hypothesis for the larger weight-loss and hepatic-fat reductions seen versus pure GLP-1 agonists.[6] Mazdutide does not include a GIP receptor arm, which distinguishes it pharmacologically from retatrutide (triple agonist) and tirzepatide (GIP/GLP-1 dual agonist).

Active research areas

  • Obesity (GLORY-1)
    GLORY-1 reported mean placebo-subtracted weight reduction of approximately 14.0% at 48 weeks on the 9mg arm and approximately 11.0% on the 6mg arm in Chinese adults with overweight or obesity — the first Phase 3 obesity readout for any GLP-1/glucagon dual agonist published in NEJM. The trial supports Innovent's pending Chinese NMPA filing.[2]
  • Type 2 diabetes (DREAMS program)
    DREAMS-1 reported A1C reductions of approximately 1.6–2.1% at 4mg and 6mg weekly versus placebo in Chinese adults with T2D, supporting the parallel diabetes filing in China.[3]
  • Hepatic fat reduction (Phase 2)
    Phase 2 work with imaging endpoints reported reductions in MRI-PDFF liver fat consistent with the GLP-1/glucagon class signal (retatrutide reported the largest hepatic-fat reduction in this class to date), suggesting mazdutide may have a role in metabolic dysfunction-associated steatotic liver disease.[1]
  • Geographic specialisation
    Mazdutide is being developed primarily for the Chinese market under license to Innovent Biologics; Lilly retains worldwide rights outside greater China and has not announced a U.S. Phase 3 obesity program. The Chinese pivotal program has prioritised dosing regimens optimised for the Chinese population (lower body-weight cohorts, different metabolic baselines).[4]
  • Comparison with retatrutide (mechanistic)
    Mazdutide and retatrutide share the glucagon arm but differ on the GIP arm; head-to-head trials have not been conducted. The published Phase 3 weight-loss results for mazdutide (~14%) are smaller than the Phase 2 retatrutide results (~24% at 48 weeks on 12mg), which suggests the GIP arm contributes meaningfully but cannot be quantified without direct comparison.[2]
Open questions & leading hypotheses (2)
  • Hypothesis: The glucagon arm of dual and triple agonists adds weight-loss efficacy without producing the historical safety concerns (hyperglycemia, cardiovascular strain) that early glucagon-agonist programs raised.
    Evidence: GLORY-1 and DREAMS-1 reported A1C reductions in T2D and weight reductions in obesity without hyperglycemia signals — the GLP-1 arm appears to dominate the net glycemic effect even with concurrent glucagon agonism.[2][3] Counter-evidence: the long-term cardiovascular and hepatic safety of chronic dual glucagon/GLP-1 receptor signalling is not yet characterised in dedicated outcome trials, and the historical caution about glucagon-receptor agonism (resting heart rate, hepatic glycogen depletion) has not been formally ruled out across years of exposure.
  • Hypothesis: Mazdutide will achieve global approval through Lilly's rest-of-world rights, not just Chinese NMPA approval.
    Evidence: Lilly retains commercialisation rights outside greater China for the molecule, and the GLORY-1 / DREAMS-1 data create a credible base for a global registration program. Counter-evidence: Lilly has not publicly announced a U.S. Phase 3 program for mazdutide and may prefer to focus resources on retatrutide and tirzepatide; the GLORY-1 weight-loss magnitude is smaller than retatrutide's Phase 2 result, which may reduce the commercial rationale for a separate Western program.
What community users report

Anecdotal — not controlled-trial evidence

Community discussion of mazdutide on r/PeptideAdmin and similar threads is much sparser than for semaglutide, tirzepatide, or retatrutide — reflecting both the China-first development path and the limited availability of research-grade material.[7] Reports that do appear most often emphasize uncertainty: dosing protocols are extrapolated from the published Phase 3 schedule (gradual titration over 8–12 weeks to a 6mg or 9mg target dose), and side-effect descriptions track the broader GLP-1/glucagon class (nausea on titration, constipation, occasional rebound hunger after discontinuation). A small cohort of self-experimenters comparing mazdutide to retatrutide subjectively report a similar appetite-suppression magnitude but a different "feel" — describing more energy and less fatigue, which they speculatively attribute to the glucagon-driven energy-expenditure effect; this is not characterised in any controlled trial. **These reports are anecdotal, are based on small numbers of users, and have not been validated in controlled trials.** Mazdutide is not approved for use outside ongoing clinical trials in any jurisdiction.

Sources & references (7)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]Ji L et al. Phase 2 study of mazdutide, a novel GLP-1/glucagon dual receptor agonist, in Chinese adults with overweight or obesity. Diabetes Obes Metab 2024;26:474–483. · PMID: 38092790 link
  2. [2]Ji L et al. Mazdutide for obesity in Chinese adults: a randomized, double-blind, placebo-controlled, Phase 3 trial (GLORY-1). NEJM 2025;392:1136–1146. · PMID: 40421736 link
  3. [3]Ji L et al. Mazdutide in Chinese adults with type 2 diabetes (DREAMS-1): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Diabetes Endocrinol 2024;12:826–838. · PMID: 37943529 link
  4. [4]ClinicalTrials.gov: GLORY-1 (NCT05607680) — Phase 3 mazdutide in Chinese adults with overweight or obesity. link
  5. [5]Coskun T et al. LY3305677 — discovery and characterization of a glucagon-like peptide-1 / glucagon dual receptor agonist for treatment of obesity. Front Endocrinol 2022 (Lilly preclinical disclosure). link
  6. [6]Müller TD et al. The new biology and pharmacology of glucagon. Physiol Rev 2017;97:721–766. · PMID: 28275047 link
  7. [7]Community report — r/PeptideAdmin mazdutide protocol discussions (subreddit), accessed May 2026. link

What Mazdutide Costs Right Now

WPA currently tracks Mazdutide from 4 distinct vendors across 5 separate Mazdutide listings. In-stock Mazdutide vials run from $67.15 to $179.99 — a 2.7x spread for the same compound. Southern Aminos holds the lowest sticker price at $67.15. Normalized to milligrams, Mazdutide costs $6.72/mg to $12.60/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Southern Aminos.

Mazdutide is stocked in 2 sizes: 10 mg listed quantity; vial count not recorded; 15 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Mazdutide listings WPA tracks are: Southern Aminos — 10mg at $67.15 ($6.72/mg), COA purity 99.66%; Glow Aminos — 10mg at $88.40 ($8.84/mg), COA purity 99.81%; Flawless Compounds — 10mg at $88.40 ($8.84/mg), COA purity 99.61%; Felix Chem — 15mg at $179.99 ($12.00/mg), COA purity 99.61%; Felix Chem — 10mg at $125.99 ($12.60/mg), COA purity 99.42%.

Mazdutide COA Coverage Across Tracked Vendors

5 of the 5 tracked Mazdutide listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 5 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.42% to 99.81%. 4 listings record more Mazdutide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 8/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Mazdutide offer. WPA's listing fields do not establish that a report was independently verified.

Mazdutide Calculator Input Observations

In lifetime Mazdutide calculator inputs, 4mg is the most frequent entered amount (5 of 10 runs). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 15 mg of listed product divided by 4 mg gives roughly 3.8 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Mazdutide Discount Codes

5 of the 5 tracked Mazdutide listings carry a WPA researcher discount code. The largest live discount is 15% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Mazdutide

Mazdutide is an investigational once-weekly GLP-1/glucagon dual-agonist peptide, sourced in research for weight and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.

Mazdutide is tracked under the Weight Loss category on WPA. Its reported half-life is ~5 days (estimated). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA- or EMA-approved.

How to Read the Mazdutide Comparison

  • Price per milligram — Every Mazdutide listing is normalized to $6.72/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 5 Mazdutide listings are marked for COA availability, and 5 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The Mazdutide comparison includes 10mg and 15mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each Mazdutide listing, refreshed on a recurring basis.

Frequently Asked Questions: Mazdutide

Is it legal and safe to buy Mazdutide for research?

In the US, Mazdutide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is an investigational GLP-1/glucagon receptor dual agonist with no approved human form, sold for laboratory research only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 5 Mazdutide listings from 4 vendors.

How do I verify a Mazdutide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Mazdutide batch. Check that the report identifies the compound (actually mazdutide, not semaglutide, tirzepatide, or an underdosed mix), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Mazdutide specifically, 5 of 5 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 5 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 8/26.

Which Mazdutide vendor should I pick?

There's no single "best" Mazdutide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Mazdutide is newer and easy to confuse with other GLP-1s, so COA recency and assayed purity carry extra weight. 4 vendors currently carry Mazdutide, and Southern Aminos holds the best true value at $6.72/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Mazdutide cost — and how do I know I'm not overpaying?

Judge Mazdutide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It commonly ships in 10 mg and 15 mg vials, and the larger size usually wins on $/mg over a full titration. Tracked Mazdutide listings currently run $6.72/mg to $12.60/mg across 10mg, 15mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Mazdutide do I need for one full cycle?

In lifetime Mazdutide calculator inputs, 4mg is the most frequent entered amount (5 of 10 runs). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 15 mg purchase quantity by 4 mg gives roughly 3.8 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Mazdutide?

Participating Mazdutide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 5 of the 5 tracked Mazdutide listings carry a code right now, the largest worth 15% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Where can I compare Mazdutide prices and listing details?

This comparison shows 5 tracked listings for Mazdutide in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.